OTC Decisions In February: 2 Switches, Label Changes For Excedrin, FeverAll, Naproxen From Biopharma

 
• By Malcolm Spicer

FDA approved two switches on one day in February, diclofenac gel and olopatadine ophthalmic drops, and stayed busy on OTCs through the month with label changes for Excedrin Migraine packaged with 2-count pouches and for Taro's FeverAll suppositories, and an NDA approval for Biopharma's naproxen.

OTC Regulatory Decisions Tracker US

More from Regulation

More from Policy & Regulation